The Lampard Inquiry has been running for more than a year since it started in September 2024. Its fifth set of hearings – held at Arundel House in London – ran from 13 to 28 October.
The inquiry heard “grave concerns” about Oxevision, which uses sensors and cameras to monitor in-patients while in their bedrooms.
Campaign group Stop Oxevision said it was a “superficial quick fix for wider systemic issues” and said many patients’ found the technology “intrusive, undignified, dehumanising and traumatising”.
Oxevsion’s manufacturer said the system played a critical role in preventing patient harm, but agreed that filming a patient 24 hours a day could possibly “constitute a very significant invasion of privacy”.
Zephan Trent, executive director of strategy, transformation and digital at EPUT, told the inquiry that improvements had been made in staff training, and that patient consent for the use of Oxevision was now actively sought.
The inquiry will hear more evidence from bereaved families when it resumes in February 2026.
Further sessions in April, July and October 2026 are expected to hear evidence from healthcare staff and corporate witnesses.